IPK in the News

[Digital Times] Born in the lab, Qurient to go public on KOSDAQ and accelerate drug discovery

2016-02-26

The lab-born, bio-venture Qurient Co. Ltd. will go public on KOSDAQ. According to MSIP, Qurient started as a subsidiary of Institut Pasteur Korea (IPK) to transition validated targets to drug candidates. Qurient has Q203, a drug-resistant tuberculosis candidate licensed from IPK, that has been approved for clinical trial phase 1 by the FDA. Also Q301, a drug candidate for atopic dermatitis that is in clinical trial phase 2 by the FDA and Q701, a drug candidate for anticancer immunity/resistant cancer that is currently on non-clinical trial. The business model is seen as a model of success for the open innovation and project management system.

Source: Digital Times (24 February, 2016)

LIST